Wexford Capital’s West Pharmaceutical WST Stock Holding History

Wexford Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-371	Closed	-$102K	–	388
2020 Q3	$102K	Buy	+371	New	+$98.2K	0.03%	145

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Wexford Capital's WST Position: Q4 2020 in Review

Wexford Capital sold out of West Pharmaceutical (WST) in Q4 2020, closing a stake of 371 shares — an estimated $102K sold.

Wexford Capital first reported a position in WST in Q3 2020 and held it in 1 quarter. The position peaked at $102K in Q3 2020. 592 funds tracked by Wall St. Rank hold WST as of Q4 2020.

Wexford Capital reported no remaining West Pharmaceutical position as of Q4 2020 after selling out during the quarter.
Wexford Capital sold 371 West Pharmaceutical shares in Q4 2020, an estimated $102K.
Wexford Capital first reported a position in West Pharmaceutical in Q3 2020 and held it in 1 quarter.
Wexford Capital's West Pharmaceutical position peaked at $102K in Q3 2020.
592 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2020.

Based on Wexford Capital's 13F filing for Q4 2020, filed 16 Feb 2021.